APA (7th ed.) Citation

R, V., ML, P., I, D., G, L., M, H., CW, S., . . . K, T. (2026). Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Reviews in endocrine & metabolic disorders, 27(2), 213. https://doi.org/10.1007/s11154-026-10027-8

Chicago Style (17th ed.) Citation

R, Vettor, et al. "Overcoming the Barriers in the Screening, Diagnosis, and Follow-up of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated Steatohepatitis (MASH)." Reviews in Endocrine & Metabolic Disorders 27, no. 2 (2026): 213. https://doi.org/10.1007/s11154-026-10027-8.

MLA (9th ed.) Citation

R, Vettor, et al. "Overcoming the Barriers in the Screening, Diagnosis, and Follow-up of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated Steatohepatitis (MASH)." Reviews in Endocrine & Metabolic Disorders, vol. 27, no. 2, 2026, p. 213, https://doi.org/10.1007/s11154-026-10027-8.